Abstract. Background/Aim: Lipid-lowering drugs have been suggested to affect neurocognitive function. This review aimed to give the latest evidence on the way these agents affect neurocognitive function based on clinical trials. Materials and Methods: A systematic search concerning original studies from 2015 to 2020 was performed through the databases PubMed, EMBASE and Cochrane, according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. The trials enrolled numerous patients and were conducted in different areas of the world. The terms used are cholesterol, lipid-lowering drugs, statins and cognitive function. Results: Eleven randomized trials met the inclusion criteria. The trials included patients suffering from cardiovascular conditions. In particular, patients with coronary heart disease, coronary heart disease risk equivalents and hypercholesterolemia were tested. The trials included evolocumab, alirocumab, statin, ezetimibe or placebo. Conclusion: Lipid-lowering drugs seem to have no significant effect on neurocognitive function, but further research specifically focused on this matter is needed.

Previous evidence has shown that the more risk factors for vascular disease one has in middle age, the greater the risk for dementia later in life. High risk cholesterol levels are among the risk factors. Evidence suggests that LDL is associated with cognitive impairment while HDL improves memory (1). Cognitive impairment relates to attention, processing speed, learning, memory and verbal flexibility. Studies of two rare diseases, Down’s syndrome and Niemann Pick type...
C, have found that cholesterol interferes with the process of cellular proliferation and this results in defective offspring of cells throughout the body, leading to various diseases, such as heart diseases and Alzheimer’s disease (2, 3). Also, it has been found that people with high cholesterol have significantly more plaques in their brains and that high cholesterol is related to a reduced risk of cognitive impairment to the elderly (4). Furthermore, it has been observed that statins are associated with some protection against cognitive impairment, but as individuals grow, protection declines (4). Lately, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have constituted a noteworthy class of medical treatment that significantly lower low-density lipoprotein cholesterol (LDL-C) via upregulation of LDL receptor availability (5). However, there is great concern whether these treatments affect neurocognitive function. This article reviews the latest evidence from randomized trials on this matter.

Materials and Methods

Three known databases (EMBASE, PubMed and Cochrane library) were systematically explored for retrieval of potentially relevant articles published from 2015 through 2020. The keywords used were cholesterol, lipid-lowering drugs, statins and cognitive function. Articles were also searched from references of the original papers and review articles. Articles concerning clinical trials were included. All duplicates were removed, and the remained records were screened for eligibility criteria. Studies suspected for bias were excluded. The research was performed in agreement with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines as presented in Figure 1. The database resulted in 11 trials that met the inclusion criteria. They are all randomized trials that compare evolocumab and alirocumab either to each other or each to placebo or a statin. The number of patients in the presented trials ranged from 250 to 27,500 and was from different sites in many countries of the world (Table I).

Results

A recently developed and effective method for lowering LDL-C levels and reducing cardiovascular diseases is the employment of human mAbs inhibiting PCSK9. Two mAbs for LDL-C reduction, evolocumab and alirocumab, have been permitted by both the FDA and European Medicines Agency and both have affirmed a notable ability in reducing LDL-C along with a promising safety profile (6). Additionally, according to the Further Cardiovascular Outcomes Research that reported the PCSK9 inhibition in patients with elevated risk trial (7), patients presenting high cardiovascular risk were investigated at first. Evolocumab has been proven to decrease cardiovascular episodes. However, patients treated with either alirocumab or evolocumab provided significantly decreased levels of on-treatment plasma cholesterol in the majority of cases (mean level 30 mg/dl: FOURIER trial and even <25 mg/dl: ODYSSEY LONG-TERM trial) (8), which is worrying in terms of potential unfortunate effects of these drugs, like neurocognitive disorders.

Some studies have observed similar neurocognitive adverse effects in patients receiving PCSK9 inhibitors and in control groups. In ODYSSEY LONG-TERM trial, medication based on alirocumab was related to a no notable increase in neurocognitive disorders such as memory impairment, amnesia and confusional state in patients being prone to present cardiovascular events. Similarly, in the reported studies ODYSSEY FH I, FH II and ODYSSEY HIGH FH and COMBO I (9-11), a small number of neurocognitive events was reported in patients treated with alirocumab [2 (0.6%) in FH I, 1 in HIGH FH and no events were reported in FH II and COMBO II] or placebo [2 (1.2%) in FH I, 1 (1.2%) in FH II, COMBO I and HIGH FH]. On the other hand, the OSLER trial cited a slight increase of neurocognitive unfavorable events in patients that received evolocumab. When 11.1 months of treatment were completed, the overall incidence of declared neurocognitive events was detected and was found to be extremely low (<1%). This outcome was not linked to the therapy of plasma LDL-C level (12). According to ODYSSEY OPTIONS I and II studies, as well as the ODYSSEY COMBO II trial (13-15), alirocumab can be compared to ezetimibe, as adjuvant therapy to maximally tolerated statin therapy in patients at increased cardiovascular risk with insufficient controlled hypercholesterolemia. Not many neurocognitive episodes appeared in either group in both trials [4 (0.8%) in patients that received alirocumab and 3 (1.2%) in ezetimibe group in ODYSSEY OPTIONS II, 1 patient in each group in ODYSSEY COMBO II trial and none in ODYSSEY OPTIONS I]. Evolocumab vs. placebo treatment was studied in RUTHERFORD-2 study and no neurocognitive events were reported (16).

The Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects (EBBINGHAUS), constitutes a randomized and double-blind study that utilized placebo-controlled tests, and was conducted to investigate the impact on neurocognitive testing, during the treatment, in patients treated with evolocumab combined with statin vs. statin alone. In order for cognitive tests to take place, the Cambridge Neuropsychological Test Automated Battery, a tablet-based tool assessing executive function, working memory, memory function, and psychomotor speed at first, weeks 24 and 48, every 48 weeks thereafter, and at the end, was utilized. The main endpoint was spatial working memory strategy index of principal function (SWMSI). The researchers aimed to investigate whether evolocumab would result in similar outcomes to placebo in the mean change in SWMSI from the beginning onwards. Investigators estimated that up to
fifteen hundred participants without cognitive issues were required in order to have 97% power to identify noninferiority; they also set the noninferiority boundary at 20% of the standard deviation. Spatial Working Memory strategy index findings were similar between patients treated with evolocumab and placebo at baseline (17.8 for each) or at the end of the trial (17.5 vs. 17.6, respectively; \( p < 0.0001 \) for noninferiority). Concerning the secondary endpoints, including additional neuropsychological items of Cambridge Neuropsychological Test Automated Battery, also provided similar results between patients randomized to medical treatment of evolocumab or placebo. Moreover, reports from patients and investigators regarding cognitive adverse events did not differ not only for placebo, but also for evolocumab. The analysis findings indicated that cognitive function was not influenced by on-treatment LDL-C status; therefore, cognitive performance in patients with an LDL-C <25 mg/dl was alike to that in patients presenting higher plasma LDL-C levels (17).

In 2017, Guigliano et al. conducted a study in which 15,281 patients were included. Patients received simvastatin 40 mg plus ezetimibe 10 mg or placebo for a median period of 6 years. As far as the neurocognitive dysfunction is concerned, neither long-term nor short-term adverse events appeared during treatment, even in patients with LDL-C levels lower than 30 mg/dl (18).

**Discussion**

Cholesterol and especially LDL cholesterol homeostasis has a pivotal role in the appropriate cellular function since it is a part of the cell membrane (19). The safety of new lipid-lowering therapies and the combinations of these agents have attracted the interest of the research community. However, the long-term effects of the use of lipid-lowering drugs on
| Study            | Participants                                                                                      | Age of participants | Countries                                                                 | Method                                                                                           | Results                                                                                                                                                        |
|------------------|--------------------------------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| FOURIER          | 27,564 (24.6% of the participants were women, with CV events and baseline LDL-C ≥70 mg/dl (1.8 mmol/l) receiving statin and/or ezetimibe) | Mean= 63 years      | N/A                                                                       | Evolocumab (either 420 mg per month or 140 mg every 14 days) or placebo as subcutaneous injections. | Similar results were observed between patients received evolocumab and placebo.                                                                                   |
| OSLER            | 1,324 (52.9% women)                                                                              | Mean= 57.1 years    | 192 sites in 18 Countries                                                | During the first year, patients were randomized to receive evolocumab, 420 mg, plus SOC or SOC alone. After the first year, all patients that remained in the trial treated with evolocumab, 420 mg, plus SOC. | Neurocognitive episode rates found to be 0% (SOC alone) and 0.4% (evolocumab plus SOC).                                                                       |
| EBBINGHAUS       | 1,204 patients who participated in FOURIER trial                                                | Mean= 63 years      | N/A                                                                       | Cognitive investigation took place utilizing the Cambridge Neuropsychological Test Automated Battery, a tablet-based tool assessing executive function, working memory, memory function, and psychomotor speed at the beginning, weeks 24 and 48, every 48 weeks thereafter, and at the end of the study. | No notable different results between the groups of the study regarding the secondary end points of scores for working memory (change in raw score, –0.52 in the evolocumab group and –0.93 in the placebo group), episodic memory (change in raw score, –1.53 and –1.53, respectively), or psychomotor speed (change in raw score, 5.2 ms and 0.9 ms, respectively). |
| RUTHERFORD 2     | 331                                                                                             | 18-80 years         | 39 sites mainly from expertise clinics in lipid, mainly attached to academic institutions in Australia, Asia, Europe, New Zealand, North America, and South Africa | Hypodermic evolocumab 140 mg every 2 weeks, evolocumab 420 mg per month, or hypodermic placebo every 2 weeks or monthly for 12 weeks. | No neurocognitive events occurred.                                                                                                                                 |
| ODYSSEY LONGTERM | 2,341 (LDL-C status of 70 mg per deciliter (1.8 mmol per liter) or more and receiving therapy with statins at the maximum tolerated dose) | ≥18 years           | 320 sites in 27 countries in Africa, Europe, and North and South America | Alirocumab (150 mg) or placebo as a 1-ml hypodermic injection every 15 days for 78 weeks. | Patients treated with alirocumab presented higher rates of neurocognitive events (1.2% vs. 0.5%).                                                                |
| ODYSSEY FH I & II| FH I, n=486; FH II, n=249                                                                     | N/A                 | 89 sites in North America, Europe, and South Africa                      | Alirocumab 75 mg or placebo every 14 days.                                                                                     | Not many neurocognitive episodes were presented with alirocumab [2 (0.6%) in FH I and none in FH II] or placebo [2 (1.2%) in FH I, 1 (1.2%) in FH II]. |
| ODYSSEY HIGH FH  | Patients with FH who are not satisfying controlled when received a maximally tolerated stable daily dose of statin for ≥4 weeks | N/A                 | N/A                                                                       | Hypodermic alirocumab 150 mg or placebo every 15 days for 78 weeks.                                                         | One patient in each group reported a neurocognitive event.                                                                                                           |
| ODYSSEY COMBO I  | 316                                                                                             | ≥18 years           | 76 sites in the United States                                           | Alirocumab (75 mg every 14 days) or placebo.                                                                                   | Not many neurocognitive events.                                                                                                                                 |
| ODYSSEY COMBO II | 720                                                                                             | N/A                 | 126 sites in Europe, Israel, North America, South Africa and South Korea | Hypodermic alirocumab 75 mg every 2 weeks plus oral placebo or oral ezetimibe 10 mg per day (plus hypodermic placebo) on a background of statin treatment. | Not many neurocognitive events presented in all groups.                                                                                                           |

CV: Cardiovascular; LDL-C: low-density lipoprotein cholesterol; N/A: non-answered; SOC: standard of care.
neurocognitive functioning still need to be investigated, as the increase in reported adverse outcome rates of 0.1 to 1.0% indicate that they are not uncommon (20).

Pooled data analysis on alirocumab showed that both patients treated with alirocumab and patients receiving placebo experienced comparable neurocognitive events (1.0% and 0.9%) and the findings of neurocognitive episodes did not differ between patients that obtained a dose of LDL-C less or more than 25 mg/dl (21). That was also the case in a pooled data analysis on evolocumab, which presented rare neurocognitive unfavorable events that were compared in the different study groups (0.1% in evolocumab vs. 0.3% in control groups) (22).

On the other hand, a more recent meta-analysis found a notable raise in neurocognitive adverse episodes among patients treated with PCSK9 inhibitor in comparison to patients who received placebo (23). However, since it included results from the Open-Label Study of Long-Term Evaluation against LDL Cholesterol trial and results obtained from its long-term extension, the same patients were tested twice in the same study. Once those findings were omitted, there was no correlation between PCSK9 therapy and neurocognitive adverse events (24). Nonetheless, in recent trials, the neurocognitive adverse events were reported by patients and no objective assessments of cognitive ability took place. Moreover, in most trials, no data on patients’ beginning cognitive level were reported.

Our review, based on the latest studies, does not show any significant repercussion of neurocognitive events in patients taking lipid-lowering drugs. However, there are some limitations that affect our conclusions, such as the missing patients’ cognitive status at the beginning of some trials, and the variety regarding the magnitude of LDL lowering, which may affect neurocognition.

Conclusion
In conclusion, neurocognitive dysfunction is a medical challenge, which is frequently met in people receiving drugs against dyslipidemia. Even though lipid-lowering drugs seem to be safe in terms of neurocognitive function, more trials specifically focusing on that issue need to be performed in order to have solid conclusions on the matter.

Conflicts of Interest
All the Authors declare that there are no conflicts of interest regarding this study.

Authors’ Contributions
GK, ED and AG designed the study. GK, LVQS and ED wrote the article. PV, NG, CD, AP, EV and AG collected the data. GK, ED, SS and AG offered scientific advice. CD, NG, AS, AP and VEG critically revised the manuscript. AG was the supervisor.

References
1. Schultz BG, Patten DK and Berlau DJ: The role of statins in both cognitive impairment and protection against dementia: A tale of two mechanisms. Transl Neurodegener 7(7): 5, 2018. PMID: 29507718. DOI: 10.1186/s40035-018-0110-3
2. Zigman WB, Schupf N, Jenkins EC, Urk TK, Tycko B and Silverman W: Cholesterol level, statin use and Alzheimer’s disease in adults with Down syndrome. Neurosci Lett 416(3): 279-284, 2007. PMID: 17353095. DOI: 10.1016/j.neulet.2007.02.023
3. Wang LJ and Song BL: Niemann-Pick C1-Like 1 and cholesterol uptake. Biochim Biophys Acta 1821(7): 964-972, 2012. PMID: 22480541. DOI: 10.1016/j.bbalip.2012.03.004
4. Svensson T, Sawada N, Mimura M, Nozaki S, Shimimoto R and Tsugane S: The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up. Transl Psychiatry 9(1): 26, 2019. PMID: 30659169. DOI: 10.1038/s41398-018-0336-y.
5. Banach M, Rizzo M, Nikolic D, Howard G, Howard V and Mikhailidis D: Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol Ther 170: 181-191, 2017. PMID: 27865998. DOI: 10.1016/j.pharmthera.2016.11.001
6. Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roels MK, Knickelbine T, Miedema MD, Khalili H, Ahmad Z, Abdulla S, Banerjee S and Brilakis ES: Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials. J Am Heart Assoc 6(12): e009610, 2017. PMID: 29223954. DOI: 10.1161/JAHA.117.006910
7. Katsiki N, Athyros VG, Mikhailidis DP and Mantzoros C: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism 74(9): 43-46, 2017. PMID: 28477848. DOI: 10.1016/j.metabol.2017.04.007
8. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, Shahawy MEI, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U and Kastelein JJF: Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16): 1489-1499, 2015. PMID: 25773378. DOI: 10.1056/NEJMoA1501031
9. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour F, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ and Farnier M: ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 36(43): 2996-3003, 2015. PMID: 26304222. DOI: 10.1093/eurheartj/ehv370
10. Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R and Stroes E: Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia and LDL-C of 160 mg/dl or higher. Cardiovasc Drugs Ther 30(5): 473-483, 2016. PMID: 27618825. DOI: 10.1007/s10557-016-6685-y
11. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U and Colhoun HM: Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I
12 Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R and Raal FJ: Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2(6): 598-607, 2017. PMID: 28291870. DOI: 10.1001/jamacardio.2017.0747

13 Bays H, Gaudet D, Weiss R, Lima Ruiz J, Watts GF, Gouni-Berthold I, Robinson J, Zhao J, Hanotin C and Donahue S: Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab 100(8): 3140-3148, 2015. PMID: 26030325. DOI: 10.1210/jc.2015-1520

14 Farnier M, Jones P, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, Du Y, Hanotin C and Donahue S: Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis 244(1): 138-146, 2016. PMID: 26638010. DOI: 10.1016/j.atherosclerosis.2015.11.010

15 Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM and ODYSSEY COMBO II Investigators: Efficacy and safety of adding alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial. Eur Heart J 36(19): 1186-1194, 2015. PMID: 25687353. DOI: 10.1093/eurheartj/ehv028

16 Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM and Gaudet D: PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet 385(9965): 331-340, 2015. PMID: 25282519. DOI: 10.1016/S0140-6736(14)61399-4

17 Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Seve PS, Robinson JG, Honapour N, Wasserman SM, Ott BR and EBBINGHAUS Investigators: Cognitive function in a randomized trial of evolocumab. N Engl J Med 377(7): 633-643, 2017. PMID: 28813214. DOI: 10.1056/NEJMoa1701131

18 Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP and Braunwald E: Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: A prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol 2(5): 547-555, 2017. PMID: 28291866. DOI: 10.1001/jamacardio.2017.0083

19 Luo J, Yang H and Song BL: Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol 21(4): 225-245, 2020. PMID: 31848472. DOI: 10.1038/s41580-019-0190-7

20 Faselis C, Imprialos K, Grassos H, Pittaras A, Kallistratos M and Manolis A: Is very low LDL-C harmful? Curr Pharm Des 24(31): 3658-3664, 2018. PMID: 30295187. DOI: 10.2174/1381612824666181008110643

21 Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, Miller K and Kastelein JJP: Safety of very low-density lipoprotein cholesterol levels with alirocumab: Pooled data from randomized trials. J Am Coll Cardiol 69(5): 471-482, 2017. PMID: 28153102. DOI: 10.1016/j.jacc.2016.11.037

22 Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Dijedjos C, Wu Y, Geller M, Uhart M, Somaratne R and Wasserman SM: PROFICIO: Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies clinical perspective. Circulation 135(19): 1819-1831, 2017. PMID: 28249876. DOI: 10.1161/CIRCULATIONAHA.116.025233

23 Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, Torguson R, Brewer HB Jr and Waksman R: The impact of pro-protein convertase subtilisin/kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. Eur Heart J 37(6): 536-545, 2016. PMID: 26578202. DOI: 10.1093/eurheartj/ehv563

24 Kołodziejczak M and Navarese EP: Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature. Atherosclerosis 247(4): 189-192, 2016. PMID: 26926598. DOI: 10.1016/j.atherosclerosis.2016.02.011

Received May 14, 2020
Revised July 20, 2020
Accepted July 24, 2020